Colorectal Cancer _ ___________________________________________________________________________
Panitumumab Panitumumab is approved for use in patients with chemotherapy- refractory metastatic colorectal cancer. In clinical trials, panitumumab as single agent or combination therapy demonstrated improvements in progression-free survival and overall survival comparable to cetuximab [308; 309; 310]. Regorafenib The safety and efficacy of regorafenib was evaluated by a single clinical trial of 760 patients with previously treated metastatic colorectal cancer. Participants were randomized to regorafenib or placebo plus best supportive care and showed a median overall survival of 6.4 vs. 5.0 months [311]. Second-Line Chemotherapy Second-line chemotherapy with irinotecan in patients treated with 5-FU/leucovorin as first-line therapy led to improved overall survival versus infusional 5-FU or supportive care [312]. Conversely, patients who progressed on irinotecan and 5-FU/ leucovorin and then received FOLFOX4 or 5-FU/leucovorin showed a median time-to-progression of 4.6 vs. 2.7 months [294]. TREATMENT OF LIVER METASTASES Approximately 15% to 25% of patients with colorectal cancer will present with liver metastases at diagnosis, and another 25% to 50% will develop metachronous hepatic metastasis after resection of the primary tumor. Only a small proportion of patients with hepatic metastases are candidates for surgical resection, but advances in tumor ablation techniques and regional and systemic chemotherapy administration have now expanded the treatment options [201]. Diagnosis In general, the imaging appearances of liver metastases are nonspecific, requiring biopsy specimens for histologic diagnosis. CT is the imaging modality of choice for evaluating hepatic metastases. CT permits better evaluation of the involvement of extrahepatic tissues, including the bones, bowel, lymph nodes, and mesentery. MRI may be superior to CT and PET scan for detection and characterization of small lesions [313]. Surgery Advances in chemotherapy have steadily improved survival in patients with colorectal cancer liver metastases, with trials now reporting a median survival of 20 months. However, with chemotherapy alone, five-year survival has been poor historically—less than 1%. This has been modestly improved in trials using FOLFOX and/or FOLFOXIRI, with five-year survival rates of 5% to 10% [290; 314]. Despite advances in chemotherapy, liver resection is the best option for achieving long-term survival and may be curative in stage IV disease confined to the liver [315; 316]. Resection of liver metastases
with clear margins is associated with a 5-year survival rate of 45% and 10-year overall survival rate of 25% [274; 317; 318; 319].
According to the National Compre-hensive Cancer Network, hepatic resection is the treatment of choice for resectable liver metastases from colorectal cancer. Complete resection must be feasible based on anatomic grounds and the extent of disease;
maintenance of adequate hepatic function is required. (https://www.nccn.org/professionals/physician_gls/pdf/ colon.pdf. Last accessed March 14, 2022.) Level of Evidence : 2a (Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.) Hepatic metastases are considered suitable for resection based on the following criteria [201]: • Limited number of lesions • Intrahepatic location of lesions • Lack of major vascular involvement • Absent or limited extra-hepatic metastases • Sufficient functional hepatic reserve Cancer Care Ontario recommends that patients with extra- hepatic metastases limited to the lungs may be suitable for liver resection if all pulmonary metastases are eradicated [317]. Studies of patients with combined liver and lung resection found three-year survival of 36% to 59%, and five-year survival of 9% to 74% [320]. The study showing 74% survival at five years calculated survival from the first metastasectomy instead of the more common second metastasectomy (usually the lungs). Median survival was 42 months when calculated from last metastasectomy [321]. Pooled data from all studies showed five-year survival of 30% [320]. Routine liver resection is not recommended in patients with portal nodal disease or non- pulmonary extra-hepatic metastases [317]. Liver resection is recommended in patients with initially unresectable liver metastases sufficiently downstaged by neoadjuvant chemotherapy [201]. If complete resection has been achieved, adjuvant chemotherapy should be used; neoadjuvant chemotherapy in patients without extra-hepatic metastases led to complete resection in 15% to 36%, and the five-year survival in these patients (33% to 42%) is similar to survival in patients with liver metastases considered resectable without chemotherapy [201; 320]. Consensus is lacking on the best regimen to convert isolated liver metastases from unresectable to resectable [201].
86
MDFL2626
Powered by FlippingBook